Genzyme, License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic

January 15, 2008 - Genzyme Corp. (Nasdaq: GENZ) announced that it has entered into a license agreement with Moffitt Cancer Center to obtain exclusive worldwide diagnostic testing rights to the discovery of the relationship of two proteins to patient response to non-small cell lung cancer (NSCLC) treatment...The expression levels of the two proteins, RRM1 and ERCC1, have been shown by Dr. Gerold Bepler, M.D., and his team from Moffitt, to correlate with patient response to platinum drugs and gemcitabine, both of which are commonly used in treating NSCLC... Genzyme's press Release-